医学
随机对照试验
体外循环
心脏外科
冠状动脉搭桥手术
临床终点
麻醉
相对风险
脑电双频指数
外科
动脉
内科学
置信区间
镇静
作者
Xinqi Cheng,Junyan Zhang,Hao Wu,Youmei Zuo,Lili Tang,Qing Zhao,Erwei Gu
标识
DOI:10.1016/j.jclinane.2020.110032
摘要
Abstract Study objective To investigate whether optimizing individualized goal-directed therapy (GDT) based on cerebral oxygen balance in high-risk surgical patients would reduce postoperative morbidity. Design This was a prospective, randomized, controlled study. Setting The study was performed in the First Affiliated Hospital of Anhui Medical University, Hefei, China, from April 2017 to July 2018. Patients 146 high-risk adult patients undergoing valve replacements or coronary artery bypass surgery with cardiopulmonary bypass (CPB) were enrolled. Intervention Patients were randomized to an individualized GDT group or usual care group. Individualized GDT was targeted to achieve the following goals: A less than 20% decline in the regional cerebral oxygen saturation (rScO2) level from baseline; a less than 20% decline in the mean arterial pressure (MAP) from baseline, as well as a bispectral index (BIS) of 45–60 before and after CPB and 40–45 during CPB. Measurements The primary outcome was a composite endpoint of 30-day mortality and major postoperative complications. Main results 128 completed the trial and were included in the modified intention-to-treat analysis. Early morbidity was similar between the GDT (25 [39%] of 65 patients) and usual care groups (33 [53%] of 63 patients) (relative risk 0.73, 95% CI 0.50–1.08; P = 0.15). Secondary analysis showed that 75 (59%) of 128 patients achieved individual targets (irrespective of intervention) and sustained less morbidity (relative risk 3.41, 95% CI 2.19–5.31; P Conclusions In high-risk patients undergoing cardiac surgery, individualized GDT therapy did not yield better outcomes, however, the achievement of preoperative individual targets may be associated with less morbidity. Trial registration Clinicaltrials.gov identifier: NCT03103633 . Registered on 1 April 2017.
科研通智能强力驱动
Strongly Powered by AbleSci AI